Amarin Corp Plc (AMRN)

[ziploc_1]

A phase 3 study for Vascepa for patients with Trigs over 500 mgs/dcl. was completed in China and announced on November 19,2020...We have been waiting for Chinese approval for nearly a year and it could come anytime now.

"The study’s primary endpoint, the percent change in TG levels from baseline to week 12, was met for the 4 gram per day VASCEPA dose group. The patient group assigned to 4 grams per day of VASCEPA showed a statistically significant median TG decrease of 19.9% (p<0.001) compared to placebo at the end of the 12-week treatment period."

We don't yet know whether Vascepa will be approved for just the high trig indication or China will also approve the global Reduce-it study for treatment of CVD as well....If so, this would expand the potential market for Vascepa by hundreds of millions of patients.

The original deal between Amarin and Eddingpharm in 2015 stipulated a 15 million dollar up front payment and milestone payments of up to 169 million dollars.